The news: Medical AI startup OpenEvidence inked a multi-year agreement with JAMA Network that gives the company access to full-text content from the American Medical Association’s 13 medical journals. AMA’s primary medical journals are JAMA and JAMA Open Network, and it publishes 11 additional periodicals spanning various clinical specialties.

More on OpenEvdience: It’s a medical search engine that provides clinical literature and evidence to physicians with specific questions about their patients. OpenEvidence brands itself as a ChatGPT for doctors. Its platform can search a repository of 35 million peer-reviewed pieces to help physicians find the best treatment for a patient, with studies, charts, and graphs to back up the output. OpenEvidence recently secured a content partnership with The New England Journal of Medicine before striking a similar deal with JAMA.

But unlike ChatGPT, OpenEvidence doesn’t hallucinate, according to the company. The tech won’t answer if there isn’t concrete evidence for a user query.

Zooming out: Physicians use AI at work, but many are hesitant to rely on the tech for critically important medical decisions, such as whether a particular treatment is the right course of action for a patient’s unique situation.

• 38% of physicians use genAI for work at least once a week, but a greater number (43%) never use it, according to a Wolters Kluwer report published this week.
• This includes clinicians who might not have genAI tools available to them, but it could indicate they’re more comfortable using AI when there’s less at stake. For instance, 53% of doctors said they use genAI for personal reasons at least once a week.
• And 85% of clinicians report being worried or uncertain about their legal liability when using AI, per a May 2025 Philips report.

OpenEvidence has been able to ease doctors’ concerns, likely because it trains its model on content from leading medical journals. Around 350,000 doctors have registered with the platform, per STAT, which is about one-third of licensed US physicians. That’s impressive growth considering the company was only founded in 2021.